» Articles » PMID: 22173168

The Interaction of Hepatic Lipid and Glucose Metabolism in Liver Diseases

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2011 Dec 17
PMID 22173168
Citations 395
Authors
Affiliations
Soon will be listed here.
Abstract

It is widely known that the liver is a central organ in lipogenesis, gluconeogenesis and cholesterol metabolism. However, over the last decades, a variety of pathological conditions highlighted the importance of metabolic functions within the diseased liver. As observed in Western societies, an increase in the prevalence of obesity and the metabolic syndrome promotes pathophysiological changes that cause non-alcoholic fatty liver disease (NAFLD). NAFLD increases the susceptibility of the liver to acute liver injury and may lead to cirrhosis and hepatocellular cancer. Alterations in insulin response, β-oxidation, lipid storage and transport, autophagy and an imbalance in chemokines and nuclear receptor signaling are held accountable for these changes. Furthermore, recent studies revealed a role for lipid accumulation in inflammation and ER stress in the clinical context of liver regeneration and hepatic carcinogenesis. This review focuses on novel findings related to nuclear receptor signaling - including the vitamin D receptor and the liver receptor homolog 1 - in hepatic lipid and glucose uptake, storage and metabolism in the clinical context of NAFLD, liver regeneration, and cancer.

Citing Articles

Proteomic and phosphoproteomic signatures of aging mouse liver.

Mohallem R, Schaser A, Aryal U Geroscience. 2025; .

PMID: 40087212 DOI: 10.1007/s11357-025-01601-0.


Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis.

Huang L, Xu R, Chen S, Lin C, Li W, Li S Mol Cancer. 2025; 24(1):73.

PMID: 40059153 PMC: 11892139. DOI: 10.1186/s12943-025-02274-1.


Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease.

Biagioli M, Fiorucci S Liver Res. 2025; 5(3):119-141.

PMID: 39957845 PMC: 11791866. DOI: 10.1016/j.livres.2021.08.003.


Activin E is a new guardian protecting against hepatic steatosis via inhibiting lipolysis in white adipose tissue.

Park S, Cho Y, Son S, Hur J, Kim Y, Oh H Exp Mol Med. 2025; 57(2):466-477.

PMID: 39948368 PMC: 11873131. DOI: 10.1038/s12276-025-01403-6.


Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics.

Ma X, Huang T, Chen X, Li Q, Liao M, Fu L Signal Transduct Target Ther. 2025; 10(1):63.

PMID: 39920130 PMC: 11806117. DOI: 10.1038/s41392-024-02104-8.